Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
December 03, 2021 10:01 ET | Neurona Therapeutics
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021 16:01 ET | Neurona Therapeutics
SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET | Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
November 04, 2021 08:00 ET | Neurona Therapeutics
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
October 20, 2021 16:02 ET | Neurona Therapeutics
SAN FRANCISCO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
June 22, 2021 08:30 ET | Neurona Therapeutics
Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
June 16, 2021 08:00 ET | Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
April 19, 2021 08:00 ET | Neurona Therapeutics
SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the...